Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,216,589
  • Shares Outstanding, K 48,859
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,580 K
  • EBIT $ -100 M
  • EBITDA $ -105 M
  • 60-Month Beta 1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.08

Options Overview Details

View History
  • Implied Volatility 97.74% ( +3.79%)
  • Historical Volatility 36.45%
  • IV Percentile 32%
  • IV Rank 23.74%
  • IV High 179.36% on 03/13/24
  • IV Low 72.32% on 10/21/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 18.74
  • Today's Open Interest 612
  • Open Int (30-Day) 1,483

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.53
  • Number of Estimates 3
  • High Estimate -0.49
  • Low Estimate -0.60
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -12.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.70 +5.06%
on 11/15/24
29.78 -16.40%
on 11/07/24
-4.10 (-14.14%)
since 10/18/24
3-Month
21.34 +16.68%
on 08/30/24
30.03 -17.08%
on 10/18/24
+1.19 (+5.02%)
since 08/16/24
52-Week
9.80 +154.08%
on 12/12/23
30.03 -17.08%
on 10/18/24
+14.50 (+139.42%)
since 11/17/23

Most Recent Stories

More News
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.9950 (+1.53%)
BGNE : 187.69 (-0.81%)
HCM : 16.83 (+0.54%)
ABBV : 166.28 (+0.78%)
ONC.TO : 1.39 (+0.72%)
ELVN : 24.90 (+2.01%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.9950 (+1.53%)
BGNE : 187.69 (-0.81%)
HCM : 16.83 (+0.54%)
ABBV : 166.28 (+0.78%)
ONC.TO : 1.39 (+0.72%)
ELVN : 24.90 (+2.01%)
Ex-congressional candidate and FTX executive's romantic partner indicted on campaign finance charges

A one-time congressional candidate and romantic partner of a convicted FTX executive has been arrested on campaign finance charges

ELVN : 24.90 (+2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO....

See More

Key Turning Points

3rd Resistance Point 25.97
2nd Resistance Point 25.45
1st Resistance Point 25.17
Last Price 24.90
1st Support Level 24.38
2nd Support Level 23.86
3rd Support Level 23.58

See More

52-Week High 30.03
Last Price 24.90
Fibonacci 61.8% 22.30
Fibonacci 50% 19.92
Fibonacci 38.2% 17.53
52-Week Low 9.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar